NASDAQ:GALT

Galectin Therapeutics Q2 2025 Earnings Results & Report

Galectin Therapeutics logo
$2.91 -0.11 (-3.64%)
As of 11/17/2026 04:00 PM Eastern

Galectin Therapeutics beat analyst earnings expectations in its Q2 2025 results, released August 14, 2025. The company reported EPS of -$0.12 versus the -$0.16 consensus estimate.

Earnings Announcement Details

Quarter
Q2 2025
Report Date
Time
Before Market Opens
Conference Call
8:00 AM ET

Galectin Therapeutics EPS Results

Actual EPS
-$0.12
Consensus EPS
-$0.16
Beat/Miss
Beat by +$0.04
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 8 quarters

Galectin Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Galectin Therapeutics Q2 2025 Earnings FAQ

Galectin Therapeutics (NASDAQ:GALT) reported earnings of -$0.12 per share for Q2 2025, beating the consensus estimate of -$0.16. The report was announced on Thursday, August 14, 2025.

Galectin Therapeutics Earnings Headlines

What the hell is going on?
Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and the shift is already underway. The dollar has lost 88% of its purchasing power since it was untethered from gold, and Fortune calls the current change the biggest shift in the world's relationship with the dollar in a generation. Stansberry says a similar reset is planned to be unveiled in Miami as soon as this December. Watch Porter Stansberry's full broadcast to see which companies could be affected.tc pixel
Galectin Therapeutics Inc GALT
See More Galectin Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Galectin Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Galectin Therapeutics and other key companies, straight to your email.

About Galectin Therapeutics

Galectin Therapeutics (NASDAQ:GALT) is a clinical-stage biotechnology company developing treatments that target galectin proteins, particularly galectin-3. The company’s research focuses on diseases involving fibrosis and inflammation, as well as potential applications in cancer.

Its lead drug candidate, belapectin (GR-MD-02), is an investigational galectin-3 inhibitor. Galectin Therapeutics has studied belapectin for liver disease, including nonalcoholic steatohepatitis (NASH) with cirrhosis and complications related to portal hypertension, and has also explored its use in cancer treatment.

The company was previously known as Pro-Pharmaceuticals before adopting the Galectin Therapeutics name. Its work is centered on drug research and clinical development rather than the sale of marketed medicines.

View Galectin Therapeutics Profile